Q1 EPS Estimates for Mersana Therapeutics Cut by Wedbush

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Research analysts at Wedbush decreased their Q1 2025 earnings per share estimates for Mersana Therapeutics in a note issued to investors on Monday, March 3rd. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.25) per share for the quarter, down from their previous estimate of ($0.24). Wedbush has a “Outperform” rating and a $4.00 price objective on the stock. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Wedbush also issued estimates for Mersana Therapeutics’ Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.94) EPS, FY2026 earnings at ($0.75) EPS and FY2027 earnings at ($0.70) EPS.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The business had revenue of $16.36 million during the quarter, compared to analysts’ expectations of $7.71 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%.

A number of other analysts have also issued reports on MRSN. Citigroup began coverage on Mersana Therapeutics in a research note on Friday, November 15th. They issued a “buy” rating and a $5.00 price target on the stock. William Blair started coverage on Mersana Therapeutics in a research note on Thursday, February 6th. They issued an “outperform” rating on the stock. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $4.25.

Mersana Therapeutics Stock Up 0.8 %

MRSN opened at $0.51 on Thursday. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35. The firm has a market cap of $63.30 million, a P/E ratio of -0.84 and a beta of 1.39. Mersana Therapeutics has a 52 week low of $0.46 and a 52 week high of $6.28. The business’s fifty day simple moving average is $0.79 and its 200 day simple moving average is $1.56.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its position in Mersana Therapeutics by 1.6% during the 3rd quarter. State Street Corp now owns 2,725,394 shares of the company’s stock valued at $5,151,000 after purchasing an additional 43,339 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in Mersana Therapeutics by 104.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 993,046 shares of the company’s stock worth $1,877,000 after acquiring an additional 507,453 shares during the period. JPMorgan Chase & Co. boosted its position in Mersana Therapeutics by 18.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,351,359 shares of the company’s stock worth $4,444,000 after acquiring an additional 374,460 shares during the period. XTX Topco Ltd boosted its position in Mersana Therapeutics by 186.0% during the 3rd quarter. XTX Topco Ltd now owns 347,255 shares of the company’s stock worth $656,000 after acquiring an additional 225,823 shares during the period. Finally, SG Americas Securities LLC boosted its position in Mersana Therapeutics by 28.7% during the 4th quarter. SG Americas Securities LLC now owns 112,291 shares of the company’s stock worth $161,000 after acquiring an additional 25,058 shares during the period. Institutional investors and hedge funds own 93.92% of the company’s stock.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.